Timeline
Dated events in the published records, newest first: regulatory decisions, guideline recommendations and editions, study dates from their registries and milestones that happened. Each date is shown as precisely as its record states it.
2021 33
-
Results first posted EMPEROR-Reduced
-
Supplemental approval Dapagliflozin (Farxiga)
-
Edition published USPSTF 2021: screening for hypertension in adults
-
Recommended Ambulatory blood pressure monitoring (ABPM)
-
Recommended Home blood pressure monitoring
-
Study completion EMPEROR-Preserved
-
Primary completion EMPEROR-Preserved
-
Primary completion Evolut Low Risk trial
-
Supplemental approval Evolocumab (Repatha)
-
Supplemental approval Sacubitril/valsartan (Entresto)
2020 21
-
Edition published 2020 ACC/AHA valvular heart disease guideline
-
Recommended Transcatheter aortic valve replacement (TAVR)
-
Primary completion PARTNER 3 trial
-
Study completion China Salt Substitute and Stroke Study (SSaSS)
-
Primary completion China Salt Substitute and Stroke Study (SSaSS)
-
Results first posted DAPA-HF
-
Results first posted ISCHEMIA (initial invasive or conservative strategy for stable coronary disease)
-
Supplemental approval WATCHMAN left atrial appendage closure device
-
Study completion Look AHEAD: intensive lifestyle intervention in type 2 diabetes
-
Study completion DAPA-CKD: dapagliflozin in chronic kidney disease
-
Primary completion DAPA-CKD: dapagliflozin in chronic kidney disease
-
Study completion EMPEROR-Reduced
-
Results first posted COAPT trial
-
Supplemental approval Dapagliflozin (Farxiga)
-
Primary completion EMPEROR-Reduced
-
Study completion FIDELIO-DKD: finerenone and kidney outcomes in type 2 diabetes
-
Primary completion FIDELIO-DKD: finerenone and kidney outcomes in type 2 diabetes
-
Results first posted Apple Heart Study Registry does not say if reached
-
Supplemental approval Rivaroxaban (Xarelto)
-
Supplemental approval Semaglutide injection for diabetes (Ozempic)
2019 20
-
Results first posted DECLARE-TIMI 58: dapagliflozin and cardiovascular outcomes in type 2 diabetes
-
Supplemental approval Dapagliflozin (Farxiga)
-
Supplemental approval Sacubitril/valsartan (Entresto)
-
Study start TRILUMINATE Pivotal trial
-
Supplemental approval CoreValve and Evolut transcatheter valves
-
Supplemental approval SAPIEN 3 transcatheter heart valve
-
Study completion DAPA-HF
-
Primary completion DAPA-HF
-
Results first posted ODYSSEY OUTCOMES (alirocumab after acute coronary syndrome)
-
Edition published 2019 ACC/AHA guideline on the primary prevention of CVD
-
Supplemental approval MitraClip
-
Primary completion COAPT trial
-
Study completion Systolic Blood Pressure Intervention Trial (SPRINT)
-
Supplemental approval Dapagliflozin (Farxiga)
-
Study completion Apple Heart Study
-
Primary completion Apple Heart Study
2018 11
-
Study start ORION-4 (inclisiran outcome trial)
-
Supplemental approval Rivaroxaban (Xarelto)
-
Study start DELIVER
-
Results first posted FOURIER (evolocumab in people with cardiovascular disease)
-
Study completion ODYSSEY OUTCOMES (alirocumab after acute coronary syndrome)
-
Primary completion ODYSSEY OUTCOMES (alirocumab after acute coronary syndrome)
2017 14
-
Supplemental approval Evolocumab (Repatha)
-
Supplemental approval Evolocumab (Repatha)
-
Study start Apple Heart Study
-
Study start TTM2
-
Supplemental approval Dapagliflozin (Farxiga)
-
Study start EARLY TAVR
-
Study start EMPEROR-Reduced
-
Study start EMPEROR-Preserved
-
Results first posted LEADER: liraglutide and cardiovascular events in type 2 diabetes
-
Supplemental approval Melody transcatheter pulmonary valve
-
Study start DAPA-HF
-
Clearance Elecsys Troponin T Gen 5 STAT assay
2016 13
-
Supplemental approval Empagliflozin (Jardiance)
-
Study completion FOURIER (evolocumab in people with cardiovascular disease)
-
Primary completion FOURIER (evolocumab in people with cardiovascular disease)
-
Supplemental approval Evolocumab (Repatha)
-
Study start SECURE Registry does not say if reached
-
Primary completion Systolic Blood Pressure Intervention Trial (SPRINT)
-
Study completion DANISH
-
Primary completion DANISH
-
Supplemental approval Rivaroxaban (Xarelto)
-
Supplemental approval Empagliflozin (Jardiance)
-
Study start Evolut Low Risk trial Registry does not say if reached
-
Study start PARTNER 3 trial
2015 19
-
Study completion LEADER: liraglutide and cardiovascular events in type 2 diabetes
-
Primary completion LEADER: liraglutide and cardiovascular events in type 2 diabetes
-
Supplemental approval Dabigatran (Pradaxa)
-
Results first posted IMPROVE-IT (ezetimibe added to simvastatin after acute coronary syndrome) Registry does not say if reached
-
Results first posted PARADIGM-HF Registry does not say if reached
-
Approval Evolocumab (Repatha)
-
Stopped early Systolic Blood Pressure Intervention Trial (SPRINT)
-
Approval Sacubitril/valsartan (Entresto)
-
Supplemental approval Empagliflozin (Jardiance)